To provide independent confirmation of the effect of SMO inhibition in CP-CML, lentiviral-mediated shRNA knockdown (KD) of SMO in primary CD34+ CP-CML cells was performed. The gene discussed is SMO; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.